Cassia auriculata: Aspects of Safety Pharmacology and Drug Interaction
Table 3
Electro-cardiograms (ECG) variables demonstrating cardiovascular safety of CA extracts.
Control (0.5% NaCMC)
C. auriculata (mg kg-1)
HA
SFE
500
1000
250
500
1000
Males
QT interval(s)
7.0 1.2
7.1 1.5
6.5 0.6
7.0 0.5
7.5 0.3
6.8 2.5
R wave amplitude (μV)
225 66
250 65
200 69
250 55
300 54
350 48
R-R interval(s)
0.3 0.01
0.25 0.01
0.22 0.05
0.29 0.03
0.22 0.08
0.28 0.09
Females
QT interval(s)
7.5 1.9
6.0 1.0
7.2 0.4
7.2 0.8
7.9 0.9
6.0 1.2
R wave amplitude (μV)
255 92
220 55
255 169
253 68
210 120
220 96
R-R interval(s)
0.22 0.02
0.19 0.02
0.20 0.03
0.23 0.03
0.29 0.05
0.30 0.09
Data are expressed as mean ± SD, n = 6. No significant difference in heart rate (R-R interval), QT interval (diastolic dysfunction) and ventricular hypertrophy (R wave amplitude) observed at increasing doses of both CA-HA and CA-SFE demonstrates safety of CA extracts.
